AgomAb Therapeutics NV ADR (AGMB)
NASDAQ: AGMBHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
AGMB stock chart
Technical analysisKey statistics
All statistics- Market cap
- $433.38M
- EPS (TTM)
- -$2.08
- Dividend yield
- None
- 52-week range
- 7.97 – 17.82
- Day range
- 8.68 – 9.35
- Volume / Avg
- 104.87K / 137.04K
- Beta
- —
- Shares outstanding
- 49.25M
52-week range
AGMB stock today
Shares of AgomAb Therapeutics NV (AGMB) finished lower on Oct 7 at $8.80, a drop of 0.45% or $0.04 per share, versus the S&P 500's 0.22% decline. Shares are 50.6% below their 52-week high of $17.82, set on Jun 29, 2026 and 10.4% above the 52-week low of $7.97, near the bottom of the past year's range. AgomAb Therapeutics NV has posted a net loss over the last twelve months (EPS of -$2.08), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About AgomAb Therapeutics NV
Company profileAgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Tim Knotnerus MSc, Ph.D.
- Headquarters
- Antwerp
- Employees
- 62
- IPO year
- 2026
- Website
- agomab.com
Analyst forecast
ForecastConsensus (7 analysts)
strong_buy
Avg. price target
$37.67+328.07%
- Strong buy 3
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
AgomAb Therapeutics NV peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ENTXEntera Bio Ltd. | 2.51 | -0.79% | $436.32M | vs AGMB |
| TECXTectonic Therapeutic Inc. | 22.71 | +1.34% | $443.97M | vs AGMB |
| EDITEditas Medicine Inc. | 2.75 | +0.73% | $422.35M | vs AGMB |
| EIKNEikon Therapeutics Inc. | 7.54 | +0.40% | $408.40M | vs AGMB |
| ZURAZura Bio Limited Class A | 4.17 | +5.30% | $399.61M | vs AGMB |
| AUTLAutolus Therapeutics plc ADR | 1.81 | +1.12% | $481.75M | vs AGMB |
| KYTXKyverna Therapeutics Inc. | 6.17 | +0.16% | $381.57M | vs AGMB |
| ALLOAllogene Therapeutics Inc. | 1.43 | -2.05% | $494.05M | vs AGMB |
Indexes, lists and sector
AgomAb Therapeutics NV stock FAQ
What is AgomAb Therapeutics NV's stock price today?
AGMB last traded at $8.80 as of Oct 7, 4:00 PM EDT, down 0.45% on the day. Prices are delayed at least 15 minutes.
Who is AgomAb Therapeutics NV's CEO?
Dr. Tim Knotnerus MSc, Ph.D. is the chief executive officer of AgomAb Therapeutics NV ADR, which has about 62 employees.
What is the AGMB 52-week high?
The 52-week high for AGMB is $17.82 and the 52-week low is $7.97. The stock is currently 50.6% below its high.